Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.

@article{Stojsi2015ProlongedSA,
  title={Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.},
  author={Jelena M Stojsi{\'c} and Tijana Stankovic and Sonja Stojkovi{\'c} and Vedrana Milinkovi{\'c} and Jelena Dini{\'c} and Zorica Milo{\vs}evi{\'c} and Zorka Milovanovi{\'c} and Nikola T Tani{\'c} and Jasna Bankovi{\'c}},
  journal={Experimental and molecular pathology},
  year={2015},
  volume={98 1},
  pages={
          27-32
        }
}
Lung cancer is the most common cause of neoplasia-related death worldwide. Accounting for approximately 80% of all lung carcinomas, the non-small cell lung carcinoma (NSCLC) is the most common clinical form with its two predominant histological types, adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Although surgical resection is the most favorable treatment for patients with NSCLC, relapse is still high, so neoadjuvant chemotherapy (NAC) is an accepted treatment modality. In this study… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro.

  • Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • 2014